Antiulcer coprescribing threatens COX-2 inhibitor cost savings

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1435, 2004-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The lowest-cost COX-2 inhibitor available through the US Medicare drug discount card programme is Merck's rofecoxib [Vioxx]

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 453, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Reports of COX-2 inhibitor-associated arrhythmias in NZ

By  

Reactions Weekly, Vol. 1, Iss. 1076, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

The clinical developments and future of the COX-2 inhibitor drugs

By Goldstein Jerome  

Inflammopharmacology, Vol. 9, Iss. 1-2, 2001-05 ,pp. : 91-99

VSP

Access to resources Recommend Favorite

COX-2 inhibitor news from ACR/ARHP

By  

Inpharma, Vol. 1, Iss. 1615, 2007-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Lumiracoxib: new COX-2 inhibitor effective in osteoarthritis

By  

Inpharma, Vol. 1, Iss. 1403, 2003-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite